BCR-ABL as a target for novel therapeutic interventions

Expert Opinion on Therapeutic Targets
T KindlerT Fischer

Abstract

The BCR-ABL oncogene is the result of a reciprocal translocation between the long arms of chromosome 9 and 22 t(9; 22). There is good experimental evidence demonstrating that BCR-ABL is the single causative abnormality in chronic myeloid leukaemia (CML), making it a unique model for the development of molecular targets. In addition to CML, BCR-ABL transcripts can be found in a minority of acute lymphoblastic leukaemias and very rarely in acute myeloid leukaemia (AML). Elucidating the molecular mechanisms and downstream pathways of BCR-ABL has led to the design of several novel therapeutic approaches. In this review, molecular targeting of BCR-ABL will be discussed based on the inhibition of protein tyrosine kinase activity, antisense strategies and immunomodulation.

References

Jan 1, 1976·Annals of the New York Academy of Sciences·J E SokalG Gomez
Feb 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·W ChenM A Cheever
Jan 1, 1992·Annual Review of Biochemistry·S Clarke
Sep 18, 1992·Cell·C L SawyersO N Witte
Jul 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·K KatoC J Der
Feb 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·S AgrawalT Pederson
Mar 15, 1990·Nature·N HeisterkampJ Groffen
Sep 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·M A KelliherN Rosenberg
Oct 13, 1988·The New England Journal of Medicine·R KurzrockM Talpaz
Dec 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·G Q Daley, D Baltimore
Nov 21, 1995·Proceedings of the National Academy of Sciences of the United States of America·M L GishizkyA M Pendergast
Jun 20, 1995·Proceedings of the National Academy of Sciences of the United States of America·R MorishitaV J Dzau
Jul 14, 1995·The Journal of Biological Chemistry·L Sepp-LorenzinoN Rosen
Mar 28, 1995·Proceedings of the National Academy of Sciences of the United States of America·E BuchdungerN B Lydon
Jan 27, 1995·Cell·G B CohenD Baltimore
Nov 1, 1994·Experimental Cell Research·N SakaiN Kuzumaki
Nov 22, 1994·Proceedings of the National Academy of Sciences of the United States of America·U KimK Nishikura
May 10, 1994·Proceedings of the National Academy of Sciences of the United States of America·T SkorskiB Calabretta
Aug 1, 1993·Seminars in Cell Biology·U Kim, K Nishikura
Dec 5, 1995·Proceedings of the National Academy of Sciences of the United States of America·A B RaitanoC L Sawyers
Jan 1, 1996·Cancer Investigation·L J Maher
Jun 21, 1996·Journal of Molecular Biology·R KronenwettG Sczakiel
Jul 9, 1996·Proceedings of the National Academy of Sciences of the United States of America·S KharbandaD Kufe
Jul 15, 1996·The Journal of Clinical Investigation·G BazzoniM E Hemler
Sep 20, 1996·The Journal of Biological Chemistry·K SenechalC L Sawyers
Jan 1, 1996·Current Biology : CB·M A CahillA Nordheim
Jul 1, 1997·The Journal of Clinical Investigation·R SalgiaJ D Griffin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.